PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29453451-0	2018	Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.	Simeprevir	114-124	beta-1,4-galactosyltransferase 1	Homo sapiens	144-147	
30070722-12	2018	Conclusions: In treatment-naive subjects without cirrhosis, AL-335 + odalasvir + simeprevir for 6-8 weeks was generally safe and highly efficacious against HCV GT1.	Simeprevir	81-91	beta-1,4-galactosyltransferase 1	Homo sapiens	160-163	
30145562-1	2018	INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF).	Simeprevir	164-174	beta-1,4-galactosyltransferase 1	Homo sapiens	89-92	
30145562-1	2018	INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF).	Simeprevir	176-179	beta-1,4-galactosyltransferase 1	Homo sapiens	89-92	
30145562-13	2018	CONCLUSIONS: Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment.	Simeprevir	157-160	beta-1,4-galactosyltransferase 1	Homo sapiens	140-143	
26096332-2	2015	Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).	Simeprevir	9-19	beta-1,4-galactosyltransferase 1	Homo sapiens	223-226	
26096332-2	2015	Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along with minimal adverse events (AEs) in patients with hepatitis C genotype 1 (HCV GT1).	Simeprevir	21-24	beta-1,4-galactosyltransferase 1	Homo sapiens	223-226